The Pancreatic Cancer Action Network has launched the Early Detection Initiative, the largest interventional study of its kind that will look at new onset diabetes and its correlation to pancreatic cancer.Â
Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder have been identified and validated by researchers at Mount Sinai.Â
Tumors consume glucose at high rates, but a team of researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.
A team of pancreatic cancer researchers was formed to predict which treatments might work best for individual pancreatic cancer patients based on the molecular traits of tumors.
A study by researchers at the UCLA Jonsson Comprehensive Cancer Center found that using percutaneous image guided needle based thermal ablation is a safe and effective adjunctive therapy for the local control of metastatic gynecologic cancers throughout lungs, liver, soft tissues in the abdomen and pelvis and bones—and in patients with advanced localized cancers unresponsive to systemic therapy.
Long-term, regular use of baby aspirin-at least 15 times per month-prior to a diagnosis of colorectal cancer may reduce the risk of death from the disease by limiting the spread of cancerous tumors pre-diagnosis, according to a study led by Cedars-Sinai Cancer researchers.
A phase III trial evaluating Keytruda (pembrolizumab) plus Lenvima (lenvatinib) in certain patients with advanced, metastatic or recurrent endometrial cancer following one prior platinum-based regimen in any setting met its dual primary endpoints of progression-free survival and overall survival.
The phase III IMpower010 study evaluating Tecentriq (atezolizumab) compared with best supportive care  met its primary endpoint of disease-free survival at the interim analysis.
The phase II/III RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo (nivolumab) versus Opdivo alone in patients with previously untreated metastatic or unresectable melanoma met its primary endpoint of progression-free survival.
Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.
